The bioavailability of oral methotrexate in children with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 40, Issue 4, 2005, Pages 445-449

  Stephens, Michael C ^a   Baldassano, Robert N ^a   York, Amy ^a   Widemann, Brigitte ^a   Pitney, Aaron C ^b   Jayaprakash, Nalini ^b   Adamson, Peter C ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Bioavailability; Crohn disease; Inflammatory bowel disease; Methotrexate; Ulcerative colitis

Indexed keywords

ALPHA TOCOPHEROL; AMPHETAMINE; CALCIUM; CELECOXIB; CETIRIZINE; CIPROFLOXACIN; FISH OIL; FOLIC ACID; INFLIXIMAB; IRON; LANSOPRAZOLE; LOPERAMIDE; MAGNESIUM; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MULTIVITAMIN; OMEPRAZOLE; PREDNISONE; ROFECOXIB; ZINC;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DIET SUPPLEMENTATION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; ENTERITIS; ENZYME INHIBITION; FEMALE; HUMAN; INTESTINE RESECTION; MALE; MALNUTRITION; PRIORITY JOURNAL; SMALL INTESTINE DISEASE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE;

EID: 16844365535     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MPG.0000157588.27125.50     Document Type: Article

References (36)

1. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724-9.
2. Fraser AG, Morton D, McGovern D, Travis S, Jewell DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:693-7.
3. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001;15:35-44.
4. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993;38:1851-6.
5. Egan LJ, Tremaine WJ, Mays DC, Lipsky JJ, Sandborn WJ. Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease. Inflamm Bowel Dis 2000;6:286-9.
6. Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999;13:1597-604.
7. Egan LJ, Sandborn WJ, Mays DC, et al. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther 1999;65:29-39.
8. Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996;71:69-80.
9. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
10. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
11. Kozarek RA. Methotrexate for refractory Crohn's disease: preliminary answers to definitive questions. Mayo Clin Proc 1996;71:104-5.
12. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
13. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000;95:1730-4.
14. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998;132:830-5.
15. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21.
16. Oren R, Moshkowitz M, Odes S. et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-9.
17. Kurnik D, Loebstein R, Fishbein E, et al. unavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:57-63.
18. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619-27.
19. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2003(1):CD003459.
20. Biancone L, Tosti C, Fina D, et al. Review article: maintenance treatment of Crohn's disease. Aliment Pharmacol Ther 2003;17 (Suppl2):31-7.
21. Fraser AG. Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol 2003;15:225-31.
22. Scribano M, Prantera C. Review article: medical treatment of moderate to severe Crohn's disease. Aliment Pharmacol Ther 2003;17 (Suppl 2):23-30.
23. Pironi L, Cornia GL, Ursitti MA, et al. Evaluation of oral administration of folic and folinic acid to prevent folate deficiency in patients with inflammatory bowel disease treated with salicylazosulfapyridine. Int J Clin Pharmacol Res 1988;8:143-8.
24. Gerson CD, Cohen N. Folic acid absorption in regional enteritis. Am J Clin Nutr 1976;29:182-6.
25. Steger GG, Mader RM, Vogelsang H, Schofl R, Lochs H, Ferenci P. Folate absorption in Crohn's disease. Digestion 1994;55:234-8.
26. Widemann BC, Balis FM, Adamson PC. Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader. Clin Chem 1999;45:223-8.
27. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res 1983;43:2342-5.
28. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
29. Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediair 1987;110:788-92.
30. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
31. Kremer JM, Petrillo GF, Hamilton RA. Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. J Rheumatol 1995;22:41-4.
32. Balis FM, Mirro J, Jr., Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988;6:1882-6.
33. Vandeputte L, D'Haens G, Baert F, Rutgeerts P. Methotrexate in refractory Crohn's disease. Inflamm Bowel Dis 1999;5:11-5.
34. Lemann M, Chamiot-Prieur C, Mesnard B, et al. Methotrexate for the treatment of refractory Crohn's disease. Aliment Pharmacol Ther 1996;10:309-14.
35. Zimmerman J. Methotrexate transport in the human intestine. Evidence for heterogeneity. Biochem Pharmacol 1992;43:2377-83.
36. Balis FM, Holcenberg JS, Poplack DG, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 1998;92:3569-77.